m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01308)
Name
3,4-diphenyl-1H-pyrrole-2,5-dione
Synonyms
2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; 3,4-diphenyl-1H-pyrrole-2,5-dione; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556
    Click to Show/Hide
Status
Investigative
Structure
Formula
C16H11NO2
InChI
1S/C16H11NO2/c18-15-13(11-7-3-1-4-8-11)14(16(19)17-15)12-9-5-2-6-10-12/h1-10H,(H,17,18,19)
InChIKey
WADCPEMKIBAJHH-UHFFFAOYSA-N
PubChem CID
2752461
TTD Drug ID
D0C3WY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Angiopoietin 1 receptor (TEK)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Angiopoietin 1 receptor (TEK) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK). [1], [2]
Cyclin-dependent kinase 1 (CDK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [3], [4]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [4], [5]
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [6], [7]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [7], [8]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [6], [7]
Cyclin-dependent kinase 4 (CDK4)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [9], [10]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [9], [10]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [8], [10]
Cyclin-dependent kinase 6 (CDK6)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 6 (CDK6) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 6 (CDK6). [4], [11]
Epidermal growth factor receptor (EGFR)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). [12], [13]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). [13], [14]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). [13], [15]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). [13], [16]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). [13], [17]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). [13], [18]
Erbb2 tyrosine kinase receptor (HER2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). [19], [20]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). [20], [21]
G1/S-specific cyclin-D1 (CCND1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [22]
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [9]
Methyltransferase-like 16 (METTL16)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [23]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [24]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [9]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [8]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [4], [22]
G1/S-specific cyclin-E1 (CCNE1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). [4], [25]
References
Ref 1 Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis. Front Cell Dev Biol. 2021 Feb 18;9:627706. doi: 10.3389/fcell.2021.627706. eCollection 2021.
Ref 2 Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55. doi: 10.1126/scitranslmed.aad9260.
Ref 3 CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression. Int J Biol Sci. 2021 Mar 15;17(5):1178-1190. doi: 10.7150/ijbs.57783. eCollection 2021.
Ref 4 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 5 KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019 Aug;38(33):6123-6141. doi: 10.1038/s41388-019-0861-z. Epub 2019 Jul 8.
Ref 6 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 7 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. doi: 10.1021/jm100080z.
Ref 8 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 9 Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020 Jul 29;11(3):485-504. doi: 10.1007/s13167-020-00220-3. eCollection 2020 Sep.
Ref 10 Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39. doi: 10.1016/j.bmc.2008.07.002. Epub 2008 Jul 8.
Ref 11 FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner. Cell Death Discov. 2021 Nov 1;7(1):329. doi: 10.1038/s41420-021-00724-5.
Ref 12 METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner. Cancer Manag Res. 2020 Dec 23;12:13173-13184. doi: 10.2147/CMAR.S286275. eCollection 2020.
Ref 13 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9. doi: 10.1016/j.ejmech.2009.01.035. Epub 2009 Feb 7.
Ref 14 METTL3 induces PLX4032 resistance in melanoma by promoting m(6)A-dependent EGFR translation. Cancer Lett. 2021 Dec 1;522:44-56. doi: 10.1016/j.canlet.2021.09.015. Epub 2021 Sep 13.
Ref 15 ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019 Apr 15;38(1):163. doi: 10.1186/s13046-019-1159-2.
Ref 16 Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism. Hepatology. 2021 Sep;74(3):1339-1356. doi: 10.1002/hep.31766.
Ref 17 YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2019 Feb 1;442:252-261. doi: 10.1016/j.canlet.2018.11.006. Epub 2018 Nov 10.
Ref 18 YTHDF3 Induces the Translation of m(6)A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell. 2020 Dec 14;38(6):857-871.e7. doi: 10.1016/j.ccell.2020.10.004. Epub 2020 Oct 29.
Ref 19 FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells. Clin Exp Metastasis. 2022 Aug;39(4):623-639. doi: 10.1007/s10585-022-10169-4. Epub 2022 May 7.
Ref 20 Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88. doi: 10.1016/j.ejmech.2007.09.018. Epub 2007 Sep 29.
Ref 21 IGF2BP2 promotes the progression of colorectal cancer through a YAP-dependent mechanism. Cancer Sci. 2021 Oct;112(10):4087-4099. doi: 10.1111/cas.15083. Epub 2021 Aug 3.
Ref 22 FTO regulates myoblast proliferation by controlling CCND1 expression in an m(6)A-YTHDF2-dependent manner. Exp Cell Res. 2021 Apr 15;401(2):112524. doi: 10.1016/j.yexcr.2021.112524. Epub 2021 Feb 27.
Ref 23 METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer. J Cell Mol Med. 2021 Jul;25(14):6602-6617. doi: 10.1111/jcmm.16664. Epub 2021 Jun 2.
Ref 24 METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol Lett. 2020 Apr;19(4):3197-3204. doi: 10.3892/ol.2020.11425. Epub 2020 Mar 3.
Ref 25 Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner. J Cell Mol Med. 2020 Mar;24(6):3521-3533. doi: 10.1111/jcmm.15042. Epub 2020 Feb 10.